854O INTERLINK-1: Phase III study of cetuximab (CTX) ± monalizumab (M) in participants (pts) with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) with disease progression on/after platinum chemotherapy (CT) and previously treated with an immune checkpoint inhibitor (ICI)
Jérôme Fayette(Université Claude Bernard Lyon 1), Roger B. Cohen(University of Pennsylvania), Makoto Tahara(National Cancer Center Hospital East), Paolo Bossi(Humanitas University), Oscar K. Serrano(AstraZeneca (France)), J-P. Machiels(Cliniques Universitaires Saint-Luc), Robert Metcalf(Cancer Research UK Manchester Institute), Lisa Licitra(University of Milan), Danny Rischin(Peter MacCallum Cancer Centre), Lillian L. Siu(University Health Network), Ulrich Keilholz(German Cancer Research Center), Kevin J. Harrington(Royal Marsden NHS Foundation Trust), Dario Ruscica(AstraZeneca (United Kingdom)), Bhumsuk Keam(Seoul National University Hospital), Robert I. Haddad(Georgetown University), Robert L. Ferris(University of Pittsburgh), Yi‐Chun Liu(Stomatology Hospital), Paramjit Kaur(AstraZeneca (United Kingdom)), Amanda Psyrri(National and Kapodistrian University of Athens), Tanguy Y. Seiwert(Georgetown University)
Cited by 32
Related Papers
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2016|5.1k
IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade
|Journal of Clinical Investigation|2017|3.9k
Cisplatin and Fluorouracil Alone or with Docetaxel in Head and Neck Cancer
|New England Journal of Medicine|2007|1.7k